Levamisole
From Wikipedia, the free encyclopedia
 |
|
|
Levamisole
|
|
| Systematic (IUPAC) name | |
| (7R)-7-phenyl-4-thia-1,6-diazabicyclo[3.3.0]oct-5-ene | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H12N2S2 |
| Mol. mass | 204.292 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Levamisole (Ergamisol®, HCl salt) is an antibiotic medication used in combination with fluorouracil to treat colon cancer.
It was discovered at Janssen Pharmaceutica in 1966.
Levamisole is a synthetic imidazothiazole derivative, and was originally used as an antihelminthic to treat worm infestations in both humans and animals. Its mechanism of action in treating colon cancer is unclear, although it has been shown to have immune-stimulating properties. It is also used infrequently to treat melanoma and head and neck cancer.
Levamisole is given orally, and is metabolized primarily by the liver.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Levamisole blocks alkaline phosphatases and is also used in biomedical research, especially in in situ hybridization protocols.
